Nam Young-Hee, Jin Hyun Jung
Department of Internal Medicine, College of Medicine, Dong-A University, Busan, Korea.
Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Allergy Asthma Clin Immunol. 2025 Apr 29;21(1):18. doi: 10.1186/s13223-025-00966-3.
Allogenic hematopoietic stem cell transplantation (HSCT) is the optimal treatment of hematologic diseases and various malignancies. Development of allergic disease in a transplant patient has been reported.
A 49-year-old male with no history of atopy underwent two allogenic HSCTs for aplastic anemia from his brother with severe atopic dermatitis 11 years ago. The patient developed eczema on whole body and an elevated peripheral blood eosinophil count of 5775 cells/µL at 3 months after the second HSCT. Despite prolonged treatment with systemic corticosteroids and immunomodulators the skin rash and elevated blood eosinophil count persisted. However, after 4 months of dupilumab therapy, the patient showed near-complete clearance of symptoms. The sustained clinical improvement was observed during 36 months treatment without adverse drug reactions.
Although rare, atopic dermatitis can occur after HSCT, and dupilumab may be safe and effective for refractory conditions.
异基因造血干细胞移植（HSCT）是血液系统疾病和各种恶性肿瘤的最佳治疗方法。已有移植患者发生过敏性疾病的报道。
一名49岁无特应性病史的男性，11年前因再生障碍性贫血接受了来自患有严重特应性皮炎的兄弟的两次异基因HSCT。第二次HSCT后3个月，患者全身出现湿疹，外周血嗜酸性粒细胞计数升高至5775个/微升。尽管长期使用全身性皮质类固醇和免疫调节剂治疗，皮疹和血液嗜酸性粒细胞计数仍持续升高。然而，在度普利尤单抗治疗4个月后，患者症状几乎完全缓解。在36个月的治疗期间观察到持续的临床改善，且无药物不良反应。
尽管罕见，但HSCT后可能发生特应性皮炎，度普利尤单抗对难治性病例可能安全有效。
